The Medicines Compan (NASDAQ: MDCO) received a number of price target changes and ratings updates during the last week:
- The Medicines Compan had its price target raised by analysts at WallachBeth from $30.00 to $38.00. They now have a “buy” rating on the stock.
- The Medicines Compan had its price target raised by analysts at Jefferies Group from $34.00 to $36.00.
- The Medicines Compan had its price target raised by analysts at Jefferies & Co. from $34.00 to $36.00. They now have a “buy” rating on the stock.
- The Medicines Compan had its price target raised by analysts at Leerink Swann from $34.00 to $35.00.
- The Medicines Compan had its price target raised by analysts at WallachBeth Capital from $30.00 to $38.00. They now have a “buy” rating on the stock.
The Medicines Compan traded down 0.71% on Tuesday, hitting $30.89. The Medicines Compan has a 52-week low of $19.37 and a 52-week high of $33.25. The stock’s 50-day moving average is currently $30.14. The company has a market cap of $1.644 billion and a price-to-earnings ratio of 33.45.
The Medicines Company is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace.
